(Total Views: 760)
Posted On: 12/09/2020 3:38:29 PM
Post# of 154974
GLSI news today was released last month but today it takes off??
The Phase III clinical trial aims to reproduce the Phase IIb study which concluded that completion of the first 6 intradermal injections of GP2 + GM-CSF safely elicited a potent immune response and reduced recurrence rates to 0% in HER2/neu 3+ patients, who received a standard course of trastuzumab after surgery.
https://www.businesswire.com/news/home/202011...ast-Cancer
The Phase III clinical trial aims to reproduce the Phase IIb study which concluded that completion of the first 6 intradermal injections of GP2 + GM-CSF safely elicited a potent immune response and reduced recurrence rates to 0% in HER2/neu 3+ patients, who received a standard course of trastuzumab after surgery.
https://www.businesswire.com/news/home/202011...ast-Cancer
(0)
(0)
